Drug Discovery, Drug Research Editorial
-
How Strategically Partnering With Academia Supports Biotech R&D Goals
9/14/2023
For early-stage biotechs, partnering with leading academic institutions can help your firm cut costs and boost the returns on R&D investments while making key research and industry connections that can assist in the development, and ultimate commercialization, of your drug/therapy products.
-
Comparing FDA And EMA Approaches To AI/ML In Drug Development & Manufacture
9/13/2023
Considering the feverish pace of innovation in the field of AI/ML and the inevitable impact on drug development, we outline the documents and guidances that the FDA and EMA have released thus far, comparing and contrasting their areas of focus and concern.
-
4 Major Trends In Lipid Nanoparticle Research
9/7/2023
When biopharmaceutical consultant Alexander Aust noticed a flood of new research on lipid and polymer nanoparticles pouring out of universities, he started collecting it. Soon, his collection grew enough to reveal trends in the research of nanoparticles in oncology, neurology, infectious disease, and, of course, nucleic acids. He provides a quick overview of those trends and the database with links to published research — more than 300 articles published since 2020.
-
How Can We Approach Cell And Gene Therapy To Treat MS?
9/5/2023
The usual approach to management and treatment of multiple sclerosis (MS) involves anti-inflammatory drugs, chemotherapy, and immunosuppressive drugs. Lately, cell and gene therapy is emerging as a breakthrough treatment option. Let's look at new approaches such as gene editing/CRISPR, stem cell therapy, and more, and how they can target specific genes associated with the MS immune response.
-
Respiratory Viral Infections: The Next Frontier For Antiviral Drug Development
8/29/2023
There is still no approved antiviral therapy for adults with RSV infections. As drug developers, we need to prioritize developing new antiviral therapies for immunocompromised patients.
-
Genomics: The 2 Biggest Trends & An Unbiased Look At Vendors
8/28/2023
Biotechs are increasingly looking into genomics as a way to accelerate drug discovery and development, and are increasingly looking to vendors for support in this. Let's look at new market research sharing the two biggest trends and an unbiased look at the prominent vendors.
-
Navigating The Murky Waters Of Patent Claims Involving AI After Amgen v. Sanofi
8/24/2023
In May 2023, the Supreme Court issued a ruling on the Section 112 enablement requirement for patents in Amgen v. Sanofi. What does this mean for patent claims involving artificial intelligence (AI) going forward? These Haynes Boone attorneys explain.
-
4 Ways Academic Medical Centers Can Capture Greater Value In The Cell & Gene Therapy Industry
8/22/2023
Academic medical centers (AMCs) are unique in the way academic functions and healthcare delivery services are co-located. With strong research capabilities, access to leading scientists, access to patients, and more, AMCs are uniquely positioned to conduct research and clinical trials, enable process development and manufacturing, and more.
-
When Batches At The CDMO Go Kaput
8/21/2023
What do you do when batches are lost at a CDMO, or other negative outcomes arise from your service provider? Here's a real-life example and answer from an experienced biotech CEO. He believes solutions start with relationships on all levels.
-
Are KRAS Inhibitors Poised To Cure Cancer?
8/21/2023
The KRAS gene, a crucial component of cell signaling pathways involved in cell growth and division, is frequently mutated in various cancers. By targeting the gene, KRAS inhibitors aim to block the aberrant signaling that promotes cancer cell proliferation. Amgen's sotorasib became the first approved KRAS inhibitor, opening up an exciting field.